149709-58-0

Basic information

• Product Name: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester
• Synonyms: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester;(R)-tert-butyl (1-([1,1'-biphenyl]-4-yl)-3-oxopropan-2-yl)carbamate;[(1R)-2-(Biphenyl-4-yl)-1-formylethyl]carbamic acid tert-butyl ester;((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl este
• CAS NO: 149709-58-0
• Molecular Formula: C₂₀H₂₃NO₃
• Molecular Weight: 325.40152
• EINECS: -0
• Product Categories: LCZ696
• Mol File: 149709-58-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 475.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.097±0.06 g/cm3(Predicted)
• PKA: 11.17±0.46(Predicted)
• CAS DataBase Reference: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester(149709-58-0)
• EPA Substance Registry System: ((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester(149709-58-0)

Safety Data

• Hazardous Substances Data: 149709-58-0(Hazardous Substances Data)

Usage

Description

((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester, also known as LCZ696 (L270005) impurity, is a chemical compound derived from the synthesis of a novel dual-acting inhibitor of angiotensin II receptor and neprilysin. It possesses structural characteristics that allow it to interact with specific biological targets, making it a potential candidate for pharmaceutical applications.

Uses

Used in Pharmaceutical Industry:
((R)-2-biphenyl-4-yl-1-forMylethyl)carbaMic acid t-butyl ester is used as an impurity in the development of LCZ696 (L270005), a novel dual-acting inhibitor of angiotensin II receptor and neprilysin. It plays a role in blood pressure reduction, which is essential for managing hypertension and related cardiovascular conditions.
The compound's involvement in the development of LCZ696 highlights its potential application in the pharmaceutical industry, particularly in the treatment of hypertension and other related conditions. Its presence as an impurity in the synthesis process may also warrant further investigation into its potential effects on the overall efficacy and safety of the drug.

Upstream product

• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 1426129-50-1 N-[(1R)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 62561-75-5 (R)-2-amino-3-(4-iodophenyl)propanoic acid 
• 673-06-3 D-(R)-phenylalanine 
• 1383027-39-1 C₁₇H₂₃F₃N₂O₇S 
• 929872-80-0 tert-butyl (R)-3-(4-hydroxyphenyl)-1-[methoxy(methyl)amino]-1-oxopropan-2-ylcarbamate 
• 70642-86-3 N-(tert-butoxycarbonyl)-D-tyrosine 
• 149709-56-8 methyl N-(tert-butoxycarbonyl)-O-[(trifluoromethyl)sulfonyl]-D-tyrosinate 
• 149818-98-4 methyl (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanoate 
• 76757-90-9 N-(tert-butoxycarbonyl)-D-tyrosine methyl ester 
• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 162972-36-3 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino>-N-methoxy-N-metyl<1,1'-biphenyl>-4-propanamide 

Downstream Products

• 149709-59-1 (R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpent-2-enoic acid ethyl ester 
• 752174-62-2 (2R,4S)-4-amino-5-biphenyl-4-yl-2-methylpentanoic acid ethyl ester 
• 1012341-48-8 (2E,4R)-5-{[1,1'-biphenyl]-4-yl}-4-{[(tert-butoxy)carbonyl]amino}-2-methylpent-2-enoic acid 
• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 
• 149709-60-4 ethyl (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpentanoate 
• 149709-59-1 ethyl 5-(4-<1,1'-biphenyl>yl)-4-<<(1,1-dimethylethoxy)carbonyl>amino>-2-methyl-2-pentenoate 
• 149709-62-6 α-ethyl (αR,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-63-7 α-ethyl (αS,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 149709-63-7 α-ethyl (γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 753421-85-1 ethyl (γS)-γ-amino-α-methyl<1,1'-biphenyl>-4-pentanoate 

Relevant articles and documents

Synthesis method of sacubitril drug intermediate

The invention relates to the technical field of synthesis of medical intermediates, in particular to a synthesis method of a sacubitril drug intermediate. The synthesis method comprises the followingsynthesis route: under the protection of nitrogen, adding a compound II and a solvent into a reaction flask, stirring to dissolve, adding diisobutylaluminum hydride according to the feeding molar ratio of compound II to diisobutylaluminum hydride (DIBAH) of 1: (1-2), and controlling the temperature, stirring for reaction, and monitoring the reaction by TLC; after the reaction is finished, adding aKHSO4/water solution for quenching reaction; combining the obtained solution with a 1N HCl solution, stirring for 5 minutes, and separating an organic phase; extracting the aqueous phase with EtOAc,combining the organic phases, drying with anhydrous sodium sulfate, and concentrating to dryness to obtain a compound I; according to the invention, diisobutylaluminum hydride is selected to replace lithium aluminum hydride which is easy to explosively decompose when encountering water. The method is simple in reaction operation, high in yield and suitable for industrial large-scale production.

Preparation method of N-Boc biphenyl alaninal

The invention discloses a preparation method of N-Boc-biphenyl alaninal, and the preparation method comprises the following steps: the N-Boc-biphenyl alaninal can be obtained by oxidation reaction of N-Boc-biphenyl alaninol and 2-iodoxybenzoic acid in an organic solvent. The method has the advantages of simple operation, high yield, high purity, low cost and little pollution, and is suitable for industrial production.

Preparation method for gamma-aminovalerate derivatives

The invention discloses a preparation method for gamma-aminovalerate derivatives. The method comprises the steps of reduction, oxidization, Wittig reaction and hydrogenation reduction with a starting material of N-((tert-butoxycarbonyl)amino-4,4-biphenyl-R-propanoate. The method has the advantages that the process route is short; chiral impurities are reduced by fixing a chiral center in the raw material; oxidized impurities are prevented from being generated by protecting the primary amine; and by using a palladium-charcoal or ruthenium catalyst for assisting a ligand to reduce ethylenic bond, the chiral selectivity is high, the yield is high and the method is suitable for large-scale industrial production.